Moreover, the 36-month beta value for CELU is 0.39. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CELU is 10.55M and currently, short sellers hold a 3.73% of that float. On April 26, 2024, CELU’s average trading volume was 97.15K shares.
CELU) stock’s latest price update
Celularity Inc (NASDAQ: CELU)’s stock price has dropped by -9.17 in relation to previous closing price of 3.38. Nevertheless, the company has seen a loss of -4.36% in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-08 that FLORHAM PARK, N.J., April 08, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (NASDAQ: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it will present in vitro data from its investigational natural killer (NK) cell therapy programs at this year’s American Society of Gene and Cell Therapy (ASGCT) Annual Meeting.
CELU’s Market Performance
Celularity Inc (CELU) has seen a -4.36% fall in stock performance for the week, with a -38.97% decline in the past month and a -11.78% plunge in the past quarter. The volatility ratio for the week is 11.99%, and the volatility levels for the past 30 days are at 10.30% for CELU. The simple moving average for the past 20 days is -30.08% for CELU’s stock, with a -7.86% simple moving average for the past 200 days.
Analysts’ Opinion of CELU
Many brokerage firms have already submitted their reports for CELU stocks, with Morgan Stanley repeating the rating for CELU by listing it as a “Underweight.” The predicted price for CELU in the upcoming period, according to Morgan Stanley is $1 based on the research report published on January 30, 2023 of the previous year 2023.
H.C. Wainwright gave a rating of “Buy” to CELU, setting the target price at $15 in the report published on June 22nd of the previous year.
CELU Trading at -34.18% from the 50-Day Moving Average
After a stumble in the market that brought CELU to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.51% of loss for the given period.
Volatility was left at 10.30%, however, over the last 30 days, the volatility rate increased by 11.99%, as shares sank -37.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.48% lower at present.
During the last 5 trading sessions, CELU fell by -4.36%, which changed the moving average for the period of 200-days by -38.32% in comparison to the 20-day moving average, which settled at $4.30. In addition, Celularity Inc saw 24.09% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CELU starting from Lim Kok Thay, who purchase 21,410,983 shares at the price of $0.25 back on Jan 12 ’24. After this action, Lim Kok Thay now owns 51,473,762 shares of Celularity Inc, valued at $5,331,335 using the latest closing price.
Hariri Robert J, the Chief Executive Officer of Celularity Inc, purchase 9,357,585 shares at $0.16 during a trade that took place back on Oct 05 ’23, which means that Hariri Robert J is holding 28,570,434 shares at $1,484,113 based on the most recent closing price.
Stock Fundamentals for CELU
Current profitability levels for the company are sitting at:
- -12.72 for the present operating margin
- -1.41 for the gross margin
The net margin for Celularity Inc stands at -12.27. The total capital return value is set at -2.59. Equity return is now at value -186.56, with -61.05 for asset returns.
Based on Celularity Inc (CELU), the company’s capital structure generated 0.67 points at debt to capital in total, while cash flow to debt ratio is standing at -1.05. The debt to equity ratio resting at 2.02. The interest coverage ratio of the stock is 3.28.
Currently, EBITDA for the company is -141.13 million with net debt to EBITDA at -0.51. When we switch over and look at the enterprise to sales, we see a ratio of 8.63. The receivables turnover for the company is 2.39for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.19.
Conclusion
To wrap up, the performance of Celularity Inc (CELU) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
